Evercore ISI analyst Maneka Mirchandaney maintained a Buy rating on Codiak BioSciences (CDAK – Research Report) yesterday and set a price target of $45.00. The company’s shares closed last Thursday at $16.73.
According to TipRanks.com, Mirchandaney is a 3-star analyst with an average return of 15.7% and a 62.5% success rate. Mirchandaney covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Inc., Finch Therapeutics Group, and Solid Biosciences.
Currently, the analyst consensus on Codiak BioSciences is a Moderate Buy with an average price target of $45.00.
The company has a one-year high of $37.85 and a one-year low of $7.90. Currently, Codiak BioSciences has an average volume of 225.6K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDAK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.